Stattic

Name: Stattic
Brand: MedChemExpress
SKU: HY-13818
Rating: 5.0 (179 reviews)

Cat. No.: HY-13818 Purity: 99.60%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Stattic is a potent STAT3 inhibitor and inhibits STAT3 phosphorylation (at Y705 and S727). Stattic inhibits the binding of a high affinity phosphopeptide for the SH2 domain of STAT3. Stattic ameliorates the renal dysfunction in Alport syndrome (AS) mice.

For research use only. We do not sell to patients.

Stattic Chemical Structure

CAS No. : 19983-44-9

Size	Price	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 66	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 66	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	USD 38	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 60	In-stock	Estimated Time of Arrival: December 31
25 mg	USD 96	In-stock	Estimated Time of Arrival: December 31
50 mg	USD 156	In-stock	Estimated Time of Arrival: December 31
100 mg	USD 240	In-stock	Estimated Time of Arrival: December 31
200 mg		Get quote
500 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 179 publication(s) in Google Scholar

173 Publications Citing Use of MCE Stattic

Proliferation Assay

: Stattic purchased from MedChemExpress. Usage Cited in: Mol Med Rep. 2023 Apr;27(4):81. [Abstract]; Stattic (5, 15, 30 µM; 4 h) markedly inhibits Y705 STAT3 phosphorylation in both senescent TC‑1 (Fig. C) and TRAMP‑C2 (Fig. D) cells in a concentration‑dependent manner.

: Stattic purchased from MedChemExpress. Usage Cited in: Ecotoxicol Environ Saf. 2022 Nov 11;248:114268. [Abstract]; Stattic (10 μM) effectively attenuates the SCCP-mediated increase in iNOS and GFAP expression in C6 cells.

: Stattic purchased from MedChemExpress. Usage Cited in: Mol Cancer. 2019 Mar 30;18(1):64. [Abstract]; Western blot analysis of HCT116 cells alone, IL6-supplemented HCT116, TAMs-co-cultured HCT116 in the presence or absence of Stattic (15 μM).

: Stattic purchased from MedChemExpress. Usage Cited in: Cell Signal. 2019 Mar;55:65-72. [Abstract]; Western blotting and densitometric analysis of p-STAT3 in Lo2 cells after 24 h of treatment with the indicated concentrations of the STAT3 inhibitor stattic.

: Stattic purchased from MedChemExpress. Usage Cited in: IUBMB Life. 2018 Jan;70(1):81-91. [Abstract]; A549 cells are treated with TG101348 (3 nM), BMS-911543 (1.5 nM), and Stattic (2.5 lM) for 24 h, and the conditioned media are collected and applied for tube formation assay in HUVECs.

: Stattic purchased from MedChemExpress. Usage Cited in: Mol Carcinog. 2017 Nov;56(11):2434-2445. [Abstract]; Cells are treated with the STAT3 inhibitor Stattic. The inhibitory action of Stattic on STAT3 phosphorylation is confirmed by Western blot.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All STAT Isoform Specific Products:

View All Isoforms

STAT3 STAT5 STAT6 STAT1

Biological Activity
Purity & Documentation
References
Customer Review

Description

Stattic is a potent STAT3 inhibitor and inhibits STAT3 phosphorylation (at Y705 and S727)^[1]. Stattic inhibits the binding of a high affinity phosphopeptide for the SH2 domain of STAT3^[2]. Stattic ameliorates the renal dysfunction in Alport syndrome (AS) mice^[3].

IC₅₀ & Target^[1]^[2]

STAT3

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	2.5 μM Compound: Stattic	Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 26396689]
A549	IC₅₀	4.4 μM Compound: Stattic	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 27718470]
ASPC1	IC₅₀	1.32 μM Compound: Stattic	Antiproliferative activity against human AsPC1 cells assessed as inhibition of cell proliferation after 72 hrs by MTS assay Antiproliferative activity against human AsPC1 cells assessed as inhibition of cell proliferation after 72 hrs by MTS assay	[PMID: 24904966]
DU-145	IC₅₀	2.5 μM Compound: Stattic	Cytotoxicity against human DU145 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human DU145 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 26396689]
HCT-116	IC₅₀	1.08 μM Compound: Stattic	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 27718470]
HCT-116	IC₅₀	2.16 μM Compound: Stattic	Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31048139]
HEL	IC₅₀	1.59 μM Compound: Stattic	Antiproliferative activity against human HEL cells harboring JAK2 V617F mutant assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human HEL cells harboring JAK2 V617F mutant assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 33689932]
HepG2	IC₅₀	3.52 μM Compound: Stattic	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31048139]
L02	IC₅₀	5.2 μM Compound: Stattic	Cytotoxicity against human LO2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human LO2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31048139]
MCF-10A	IC₅₀	6.11 μM Compound: Stattic	Cytotoxicity against human MCF10A cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human MCF10A cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31048139]
MCF7	IC₅₀	1.7 μM Compound: Stattic	Antiproliferative activity against human MCF7 cells expressing low levels of STAT3 assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells expressing low levels of STAT3 assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 33689932]
MCF7	IC₅₀	2.16 μM Compound: Stattic	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 26396689]
MCF7	IC₅₀	2.36 μM Compound: Stattic	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 27718470]
MCF7	IC₅₀	3.6 μM Compound: Stattic	Antiproliferative activity against ER-positive human MCF7 cells assessed as inhibition of cell proliferation after 72 hrs by MTS assay Antiproliferative activity against ER-positive human MCF7 cells assessed as inhibition of cell proliferation after 72 hrs by MTS assay	[PMID: 24904966]
MCF7	IC₅₀	3.71 μM Compound: Stattic	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31048139]
MDA-MB-231	IC₅₀	1.56 μM Compound: Stattic	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 26396689]
MDA-MB-231	IC₅₀	1.68 μM Compound: Stattic	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 27718470]
MDA-MB-231	IC₅₀	1.81 μM Compound: Stattic	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31048139]
MDA-MB-231	IC₅₀	2.64 μM Compound: Stattic	Antiproliferative activity against human MDA-MB-231 cells overexpressing STAT3 assessed as reduction in cell growth incubated for 48 hrs by CCK-8 assay Antiproliferative activity against human MDA-MB-231 cells overexpressing STAT3 assessed as reduction in cell growth incubated for 48 hrs by CCK-8 assay	[PMID: 32603980]
MDA-MB-231	IC₅₀	2.89 μM Compound: Stattic	Antiproliferative activity against ER-negative and triple-negative human MDA-MB-231 cells assessed as inhibition of cell proliferation after 72 hrs by MTS assay Antiproliferative activity against ER-negative and triple-negative human MDA-MB-231 cells assessed as inhibition of cell proliferation after 72 hrs by MTS assay	[PMID: 24904966]
MDA-MB-435S	IC₅₀	1.87 μM Compound: Stattic	Cytotoxicity against human MDA-MB-435S cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-435S cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 26396689]
MDA-MB-453	IC₅₀	4.4 μM Compound: Stattic	Antiproliferative activity against human MDA-MB-453 cells expressing low levels of STAT3 assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-453 cells expressing low levels of STAT3 assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 33689932]
MDA-MB-468	IC₅₀	1.92 μM Compound: Stattic	Antiproliferative activity against human MDA-MB-468 cells overexpressing STAT3 assessed as reduction in cell growth incubated for 48 hrs by CCK-8 assay Antiproliferative activity against human MDA-MB-468 cells overexpressing STAT3 assessed as reduction in cell growth incubated for 48 hrs by CCK-8 assay	[PMID: 32603980]
MDA-MB-468	IC₅₀	1.92 μM Compound: Stattic	Antiproliferative activity against human MDA-MB-468 cells overexpressing STAT3 assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-468 cells overexpressing STAT3 assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 33689932]
PANC-1	IC₅₀	2.9 μM Compound: Stattic	Cytotoxicity against human PANC1 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human PANC1 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 26396689]
PANC-1	IC₅₀	3.77 μM Compound: Stattic	Antiproliferative activity against human PANC1 cells assessed as inhibition of cell proliferation after 72 hrs by MTS assay Antiproliferative activity against human PANC1 cells assessed as inhibition of cell proliferation after 72 hrs by MTS assay	[PMID: 24904966]

In Vitro

Stattic (20 μM; 24 hours) inhibits STAT3 phosphorylation (Y705) and selectively inhibits P-STAT3 as demonstrated by the lack of inhibition of P-ERK1/2 in ALDH⁺ and D44⁺/CD24⁺ subpopulations of Panc-1 and HPAC pancreatic cancer cell lines^[1].
Stattic (2.5, 5, 10 μM; for 4 h) significantly reduces the nuclear level of pSTAT3 and survivin in PC3M-1E8 cells at 10 μM. Stattic (2.5-10 μM; for 24 h) inhibits IL-6-induced STAT3 activation in a dose-dependent manner^[2].
Stattic (2.5, 5, 10 μM; for 48 h) suppresses both the growth and induces apoptosis prostate cancer cells (PC3M-1E8 cells) with 10 μM. Stattic does not induce significant cell apoptosis with 2.5 μM, 5 μM^[2].
Stattic (2.5, 5, 10 μM; for 48 h) shows significant S phase accumulation^[2].
Stattic can not lead to significant morphological changes or apoptosis and has little STAT3 phosphorylation in A2780 cells and HUVECs^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Stattic (10 mg/kg; i.p.; three times per week for 10 week) ameliorates the renal dysfunction in Alport syndrome (AS) mice^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Age-matched wild-type (WT) C57BL/6 mice^[3]
Dosage:	10 mg/kg
Administration:	IP; three timesper week for 10 week
Result:	Increased levels of proteinuria, BUN and serum creatinine. Significantly suppressed the gene expression levels of renal injury markers (Lcn2, Kim-1), pro-inflammatory cytokines (Il-6, KC), pro-fibrotic genes (Tgf-β, Col1a1, α-Sma) and Mmp9.

Molecular Weight

211.19

Formula

C₈H₅NO₄S

CAS No.

19983-44-9

Appearance

Solid

Color

Off-white to yellow

SMILES

O=[N+](C1=CC=C(C=CS2(=O)=O)C2=C1)[O-]

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL (236.75 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	4.7351 mL	23.6754 mL	47.3507 mL
5 mM	0.9470 mL	4.7351 mL	9.4701 mL
10 mM	0.4735 mL	2.3675 mL	4.7351 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (11.84 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (11.84 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 1.67 mg/mL (7.91 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.60%

Select Batch:

Data Sheet (279 KB) SDS (393 KB)

COA (252 KB) HNMR (238 KB) RP-HPLC (245 KB) Elemental Analysis Report (111 KB)

Handling Instructions (2659 KB)

References

[1]. Lin L, et al. STAT3 as a potential therapeutic target in ALDH+ and CD44+/CD24+ stem cell-like pancreatic cancer cells. Int J Oncol. 2016 Oct 12. [Content Brief]

[2]. John S McMurray, et al. A new small-molecule Stat3 inhibitor. Chem Biol. 2006 Nov;13(11):1123-4. [Content Brief]

[3]. Tsubasa Yokota, et al. STAT3 inhibition attenuates the progressive phenotypes of Alport syndrome mouse model. Nephrol Dial Transplant. 2018 Feb 1;33(2):214-223. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	4.7351 mL	23.6754 mL	47.3507 mL	118.3768 mL
	5 mM	0.9470 mL	4.7351 mL	9.4701 mL	23.6754 mL
	10 mM	0.4735 mL	2.3675 mL	4.7351 mL	11.8377 mL
	15 mM	0.3157 mL	1.5784 mL	3.1567 mL	7.8918 mL
	20 mM	0.2368 mL	1.1838 mL	2.3675 mL	5.9188 mL
	25 mM	0.1894 mL	0.9470 mL	1.8940 mL	4.7351 mL
	30 mM	0.1578 mL	0.7892 mL	1.5784 mL	3.9459 mL
	40 mM	0.1184 mL	0.5919 mL	1.1838 mL	2.9594 mL
	50 mM	0.0947 mL	0.4735 mL	0.9470 mL	2.3675 mL
	60 mM	0.0789 mL	0.3946 mL	0.7892 mL	1.9729 mL
	80 mM	0.0592 mL	0.2959 mL	0.5919 mL	1.4797 mL
	100 mM	0.0474 mL	0.2368 mL	0.4735 mL	1.1838 mL

Stattic Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Stattic19983-44-9STATApoptosisp-STAT3Y705S727SH2AlportsyndromeP-ERK1/2PC3M-1E8prostatecancerS phaseInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社
Product Name			Salutation
Applicant Name *			Email Address *
Phone Number *			Organization Name *
Department *			Requested quantity *
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Stattic

Customer Review

Stattic Related Antibodies

173 Publications Citing Use of MCE Stattic

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All STAT Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Stattic Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Stattic Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report